The premise, IIUC, is that obesity is driven partly by mucosal overgrowth on the duodenum. This thicker-than-expected layer of mucus is less porous, which leads your digestive system to underestimate the number of calories you've consumed. Revita basically re-surfaces the duodenum.
So, the idea is that you get to a lower weight with the GLP-1 drugs, and then Revita can hopefully reset your set point there.
Their first clinical trial is still in progress, but I think it's interesting to watch.
You can find evidence of this in the literature, but it’s absurdly understudied, because big pharma would rather sell you a subscription to life.
Fortunately there are many good people in the world, especially in the field of medicine, who want to help their patients unconditionally. So there are glimmers of hope, like some of the top cardiologists in the world going against status quo and treating patients with fasting regimes instead of surgery.